AbbVie (NYSE:ABBV) First Quarter 2025 Results

Key Financial Results

• Revenue: US$13.3b (up 8.4% from 1Q 2024).
• Net income: US$1.28b (down 6.1% from 1Q 2024).
• Profit margin: 9.6% (down from 11% in 1Q 2024).
• EPS: US$0.72 (down from US$0.77 in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

AbbVie Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) missed analyst estimates by 35%.

Looking ahead, revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

The company's shares are down 5.9% from a week ago.

Risk Analysis

Be aware that AbbVie is showing 5 warning signs in our investment analysis that you should know about...

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.